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Cancer gene panelsThe recent advances in next generation sequencing technologies have made it possible to implement genomic
medicine in developing countries such as Sri Lanka where capacity for utilization is limited. This paper aims to
describe our initial experience and challenges faced in integrating genomic medicine into routine clinical prac-
tice. Using the Illumina MiSeq Next generation sequencing (NGS) platform and an in-house developed bioinfor-
matics pipeline/workﬂow, we successfully implemented clinical exome sequencing for rare disorders, complex
disorders with unusual coexisting phenotypes, and multigene cancer panel testing for inherited cancer syn-
dromes. The advantages of implementing these tests, the challenges for bioinformatics analysis and reporting,
the ethical, legal, and social implications of moving from genetic to genomic counseling, and special policy issues
related to implementing these tests are further discussed. The implementation of genomicmedicine into our rou-
tine clinical practice has facilitated improved care for our patients, attesting to the ability of resource limited
countries to improve care using advanced genomic technology.ulty of Medicine, U
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In recent years, genomic medicine has been hailed as an important
tool in the implementation of predictive and personalized medicine
(Biesecker and Green, 2014). The utility of clinical exome sequencing
(CES) for the rapid and accurate identiﬁcation of known and novel dis-
ease genes in families segregating rare Mendelian forms of disease is
now well established (Williams et al., 2016). Since its inception, geno-
mic medicine has continued to gain momentum across the entire clini-
cal spectrum from risk assessment in healthy individuals, through
diagnosis and prognosis to genome-guided treatment in patients with
rare and complex diseases (Manolio et al., 2013; McCarthy et al.,
2013). CES, where exome sequencing is focused only on the genes for
which the function is known, has enabled small labs with limited bioin-
formatics capabilities to practice genomic medicine (Lee et al., 2014).
Research in the ﬁeld of cancer genetics has demonstrated that all
cancers arise as a result of variants which confer a growth advantage
upon the cells in which they have occurred, giving rise to tumors
(McCarthy et al., 2013). Identifying the genes involved in predisposition
to cancer is known to have potential utility in risk managementniversity of
der the CC BY-NC(Rahman, 2014). Genetic testing is not so easy because there are more
than 100 cancer predisposing genes and an individual with a family his-
tory of cancer would need to be tested gene by gene to identify themu-
tation. However, this limitation has now been overcome through the
availability of a multigene cancer gene panel test where multiple
genes that are known to cause inherited cancer syndromes can be tested
at once using the next generation sequencing (NGS) platforms faster
and cheaper than testing a single gene. It provides a rapid and econom-
ical solution to single-gene tests as it can analyse multiple genes simul-
taneously saving both time and money.
Although Sri Lanka is a developing country, advances in other parts
of the world are reaching its shores faster than ever before due to wide-
spread penetration of the internet, which is accessed by a highly literate
and technology savvy population. As a result of increasing public aware-
ness, the demand for genetic testing to end the diagnostic odysseys of
undiagnosed conditions as well to identify hereditary predisposition
to cancer is growing rapidly. Therefore, we felt the urgent need to im-
plement NGS services in Sri Lanka. In order to achieve this, we had to
improve the existing laboratory infrastructure, train our staff, and
focus especially on developing our in-house bioinformatics capabilities.
In addition,we had to convince technology suppliers thatwewere com-
mitted to implementing NGS services. The main challenge we expected
to encounterwas the issue ofwhopays for the tests and establishing the
test pricing. These continue to be challenges because the cost of service
contracts, reagents, and related consumables etc. are constantly escalat-
ing, and a service dependent on payment by the customer cannot sur-
vive on narrow proﬁt margins. In spite of these however, by-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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that otherwise patients with a spectrum of genetically heterogeneous
rare Mendelian disorders and providers could have only dreamt of in a
third world country.
Implementing CES and a multigene cancer panel have enabled us to
diagnose and successfullymanage patientswith rare disorders, complex
disorders with unusual coexisting phenotypes, and inherited cancer
syndromes, all of whom hitherto lacked a precise genetic diagnosis
and appropriate treatment. We plan to continue providing these ser-
vices in the country as we continually seek potential solutions to the
existing challenges for sustainability through increased public-private
partnerships, research funding, international networking, and locally
generated revenue from consultancy services. In this paper we describe
novel missense mutations that were identiﬁed using NGS. These have
not been reported in scientiﬁc literature and were also absent in our
existing database of de-identiﬁed Sri Lankan exome/genome sequences.
2. Implementation
Patients are referred to our unit to obtain a genetic diagnosis by the
Specialists managing them. As a routine practice at our centre, pre-test
counseling is provided and written informed consent obtained from
all patients prior to genetic testing.
CES was performed using the TruSight One® exon enrichment tech-
nology on the IlluminaMiSeq NGS platform for undiagnosed, suspected
genetic conditions. The CES kit contains 4836 clinically relevant genes.
CESwas conducted as trio-CES (both parents and their affected child se-
quenced simultaneously) to effectively detect de novo and compound
heterozygous variants or as proband-CES (only the affected individual
sequenced) when parental samples were not available. The trio-CES
test has the potential beneﬁt of ruling out many heterozygous rare var-
iants as causal in the affected individual because transmission is ob-
served from an unaffected parent (Lee et al., 2014).
Sequencing was followed by bioinformatics analysis. Single nucleo-
tide polymorphisms (SNPs) and Indels were identiﬁed from the
paired-end sequenced data using an in-house developed variant calling
and annotation pipeline (vide infra). Benign variants were ﬁltered out
using a virtual gene panel, consisting of genes with conﬁrmed associa-
tion to the underlying conditions. Resultant variants were further scru-
tinized for their functional impact on the protein, availability in public
databases and the level of conservation in the resided region.
The cancer gene panel we implemented tests 94 genes associated
with both common (e.g. breast, ovarian, uterine, colorectal, prostate,
and thyroid) and rare hereditary cancers. It was performed using the
TruSight Cancer® sequencing kit produced by Illumina, USA. Sequenc-
ing was followed by analysis of the data on a bioinformatics pipeline.
Paired end sequencing data was ﬁrst aligned to the GrCh37 human ref-
erence sequence using BWA-mem algorithm. Thereafter, the resultant
sam ﬁle was converted to a binary formatted alignment ﬁle (bam)
using sam tools. Duplicate reads were removed from the bam ﬁle
using picard tools. Resultant reads were re-aligned around indels and
variants were discovered using GATK. Annotation was done using
SNP-eff with dbSNP, 1000 Genomes, Exome Variant Server, Exome Ag-
gregation Consortium, phastCons100way, ClinVar, locus speciﬁc data-
bases, and in-silico analysis using Mutation Taster, SIFT, Polyphen2,
and Provean was carried out to determine the functional signiﬁcance
of the variants identiﬁed. In addition, other affected and non-affected
family members were tested for further conﬁrmation when required.
3. Results
So far, we have successfully implemented CES and the multigene
cancer panel test to identify pathogenic mutations in N30 probands
with a spectrum of genetically heterogeneous rareMendelian disorders.
Their ages ranged from 8 months to 70 years, with some individuals
having spent several decades without a precise diagnosis. Amongthose tested, some of the novel pathogenic variants and their associated
phenotypes discovered are reported here. They include the following:
Type1 hyper lipoproteinaemia caused by LPL c.808C N G, p.Arg270Gly;
progressive distal peripheral neuropathy in a patient with non-insulin
dependent diabetesmellitus caused byMYH14 c.795C NA, p.Asp265Glu;
and familial adenomatous polyposis cause by APC c.7781C N G,
p.Ser2594Cys. Detailed genotypic-phenotypic features of these 3 cases
are described below.
3.1. Case 1
An eight month old male child born to consanguineous parents, who
was clinically diagnosed with hyperlipidemia and hepatosplenomegaly
was referred for genetic testing. His lipid proﬁle showed: serum triglycer-
ides: 1500.2 mg/dl (10–200 mg/dl), serum cholesterol: 196.4 mg/dl
(140–239 mg/dl), HDL cholesterol: 12.3 mg/dl (35–85 mg/dl), and VLDL
cholesterol: 300.04 mg/dl (10–41 mg/dl). Parents were normal with no
family history of dyslipidemic conditions. A missense mutation in the Li-
poprotein lipase (LPL) gene, NM_000237: c.808C N G [NP_000228:
p.Arg270Gly] causing autosomal recessive Type 1 hyperlipoproteinemia
was detected. The patient was a homozygote for the mutation while
both parents were heterozygote carriers.
NM_000237: c.808CNG [NP_000228: p.Arg270Gly in the LPL gene, is
a novel missense mutation which has never been reported in the scien-
tiﬁc literature. It was also absent in our existing database of de-
identiﬁed Sri Lankan exome/genome sequences. The Human Gene Mu-
tation Database (HGMD) records a variant in the same position with a
different alternative allele (T) coding for a different amino acid (Cys),
which is pathogenic for Lipoprotein lipase deﬁciency, NM_000237:
c.808C N T [NP_000228: p.Arg270Cys]. This mutation resides in a highly
conserved region (PhastCons score = 1), and was predicted to be path-
ogenic on bioinformatics functional analysis. MutationTaster classiﬁed
this variant as ‘disease causing’ with a probability of 0.999 whilst
PolyPhen-2 predicted this variant as ‘probably damaging’ with the
highest available score (1.00) using both HumDiv and HumVar predic-
tion models. Provean also predicted this mutation to be ‘deleterious’
with a score of−6.46 (cutoff b−2.5) and SIFT predicted it to be ‘dam-
aging’ with 0.000 score (cutoff b0.05). This ﬁnding is beneﬁcial not
only in providing appropriate therapeutic management for the proband
but also in offering genetic counseling for the family with regard to the
risk associated with intermarriage within the parents' families (a prac-
tice which was common in the community to which the family
belonged), the detection of carrier/presymptomatic relatives and prena-
tal diagnosis.
3.2. Case 2
A 47-year-old male who was clinically diagnosed with non-insulin
dependent diabetes mellitus (NIDDM) and grade I distal sensory pe-
ripheral neuropathy of the lower limbs was referred for genetic testing.
Both parents had NIDDM. Two of his male siblings and his father were
also affectedwith distal sensory peripheral neuropathy. Amissensemu-
tation in theMYH14 gene, NM_001145809: c.795C N A [NP_001139281:
p.Asp265Glu] that is associated with sensory peripheral neuropathy
was detected. The patient was a heterozygote for the mutation. This is
a novel missensemutation, which has never been reported in the scien-
tiﬁc literature and was also absent in our existing database of de-
identiﬁed Sri Lankan exome/genome sequences. This mutation resides
in a highly conserved region of the gene (PhastCons score = 0.996),
and was predicted to be pathogenic on bioinformatics functional analy-
sis. MutationTaster classiﬁed this variant as a ‘disease causing’mutation
with a probability of 0.999 while PolyPhen-2 predicted it as ‘probably
damaging’ with a score of 0.996. Provean also predicted this mutation
to be ‘deleterious’ with a score of−3.76 (cutoff b−2.5) and SIFT pre-
dicted it to be ‘damaging’ with a 0.028 score (cutoff b0.05). This case
highlights the value of exome sequencing in elucidating the exact
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have all along beenmisattributed to themicrovascular complications of
NIDDM arising from poor glycemic control rather than the underlying
hereditary neuropathy. Further functional studies, however, will be re-
quired to ascertain the pathogenicity of this variant.
3.3. Case 3
A 70 year old female who was clinically diagnosed with familial ade-
nomatous polyposis (FAP) was referred for genetic testing. She had a
strong family history with 3 of her ﬁrst degree relatives affected with
FAP. A missense mutation in the APC gene, NM_000038.4: c.7781C N G;
[NP_000029.2: p.Ser2594Cys] was detected. This mutation resides in a
highly conserved region of the gene (PhastCons score = 0.995), and
was predicted to be likely pathogenic on bioinformatics functional analy-
sis. The patient was a heterozygote for the germline mutation.
MutationTaster classiﬁed this variant as a ‘disease causing’ mutation
with a probability of 0.973 while PolyPhen-2 predicted it as ‘benign’.
Provean also predicted this mutation to be ‘tolerated’ with a score of
−1.05 (cutoff b−2.5) but SIFT predicted it to be ‘damaging’ with a
0.029 score (cutoff b0.05). This is a rare mutation that has not previously
been reported in association with FAP in the scientiﬁc literature. The
identiﬁcation of this familial mutation is beneﬁcial for the clinician in de-
cision making regarding speciﬁc management strategies for improving
clinical outcome in the patient and also has implications for both affected
and unaffected members of the family who are at risk.
4. Discussion
The cases above highlight the importance of implementing NGS
technology to diagnose difﬁcult to diagnose cases as well as to discover
novel pathogenic mutations. The implementation of genomic medicine
into our routine clinical practice has facilitated the rapid, accurate and
affordable diagnosis of rare and complex genetic diseases in a compre-
hensive, cost effective and timely manner in Sri Lanka. It further lead
to important new discoveries to add to our de-identiﬁed Sri Lankan da-
tabase. It is important tomention that ideally, in the case of novel muta-
tions, functional studies are needed to thoroughly understand the
pathogenicity of these variants.
The genotypic conﬁrmation of these diseases allows for targeted
treatment, where therapies are available, leading to a positive impact
on patient care and a holistic understanding of the disease conditions.
In addition, it provides accurate estimates of recurrence risk and facili-
tate preconception intervention or prenatal diagnosis for the affected
patient and/or affected or at-risk relatives. In adult-onset disease, one
of the most useful outcomes of successfully identifying the causative
variant is the subsequent detection of pre-symptomatic, at-risk relatives
for whom screening or preventive therapy might improve the clinical
outcome. Examples include enhanced surveillance or prophylactic risk
reduction measures for patients found to have a genetic susceptibility
to cancer (Biesecker and Green, 2014).
We have encountered several challenges in implementing genomic
medicine into our routine clinical practice. Some of these issues are
discussed below. The challenge for bioinformatics and reporting, in-
cludes the interpretation of variants in the context of the phenotypic
data, dealing with variants of uncertain clinical signiﬁcance, non-
representation of variants found in the Sri Lankan population in public
databases, and dealing with incidental ﬁndings. In the case of incidental
ﬁndings, our current practice is to use the recently published guidelines
of the American College of Medical Genetics (ACMG) to determine
which genes, variants and speciﬁc conditions should be considered for
reporting (Green et al., 2013; Richards et al., 2015). We are constantly
ﬁne tuning and optimizing our in-house bioinformatics pipeline and
workﬂow to address the other bioinformatics related challenges.
The ethical, legal, and social implications of moving from genetic to
genomic counseling, managing patient privacy in an atmosphere ofcollaborative, open-access public data sharing, and working with fami-
lies encountering legal prohibition of selective termination of pregnan-
cies based on genetic information are some of the other challenging
concerns related to genomic medicine we have had to tackle. As a rou-
tine practice at our centre, all those undergoing genetic testing are of-
fered comprehensive pre- and post-test counseling and informed
consent obtained prior to testing. Genetic counseling allows individuals
an opportunity to learn howheredity contributes to disease risk, under-
stand their personal risk of developing the disease, understand their op-
tions for managing their disease risk and encourages adoption of risk-
reducing behaviors that are appropriate for them.
Special issues related to implementing these tests stemming from
policy issues related to ﬁnancing tests and perception about the useful-
ness of these tests among policymakers and administrators posed addi-
tional challenges. Currently, there is non-coverage of all genomic tests
by the insurance companies in Sri Lanka and no government subsidies
have been put in place to assist patients undergoing genetic testing.
Thus, patients have had to bear the burden of ﬁnancing these tests all
by themselves. To make these tests affordable to patients we have
priced CES at the equivalent of approximately USD 1000/− [LKR
150,000] and the multigene cancer panel at USD 550/− [LKR 75,000].
Further cost reductions in the future and physician education would
make it possible for us to ensure more widespread use of our NGS ser-
vices. We have discussed the challenges we face in physician education
elsewhere (de Abrew et al., 2014).
In addition, a robustmeans of integrating genomic data into existing
health records is needed, with consideration of not only data storage
formats and privacy issues but also appropriate clinical decision support
tools for prompting point of care use of genomic information and deliv-
ering it to healthcare providers in an easily interpretable format
(McCarthy et al., 2013). Alongside this, there is also the need for all
health care professionals in the country to be trained on speciﬁc core
competencies regarding knowledge, skills, and attitudes in order to ef-
fectively implement genomic medicine at different levels of healthcare
delivery. Professional practice guidelines also need to be developed
(Korf et al., 2014; Manolio et al., 2015).
It is believed that in the foreseeable future, as these challenges are
gradually overcome, more routine implementation of CES and cancer
gene panel tests will improve molecular diagnostic success rates in pa-
tients across the spectrum of genetically heterogeneous disorders (Lee
et al., 2014). In addition, routine implementation of other gene panel
tests for indications such as inherited cardiac disorders, inherited neu-
ropathies, and inherited myopathies to name a few will also lead to bet-
ter diagnostic success rates and appropriate treatment and possibly
prevention strategies.
Developing the researchers' skills is one of the most important as-
pects in advancing genome research in the country, which is necessary
to advancing genomicmedicine nationally. This development should be
in both experimental and computational skills. We believe that educa-
tion and training in the basics of genomics and bioinformatics should
begin at the undergraduate level with more advanced training at grad-
uate levels. Furthermore,we hope to generate research funding, encour-
age international collaborations, and organize specialized training
programs including workshops and postgraduate courses as possible
potential solutions for the sustainable future development of genomic
medicine services and research in the country.
In conclusion, despite the challenges faced, successful implemen-
tation of genomic medicine into our routine clinical practice has fa-
cilitated the rapid and accurate diagnosis of rare and complex
genetic diseases in a comprehensive, cost effective and timely man-
ner and, of note, in the context of a developing country. Future
plans for enlarging the current efforts and reaching out to a larger
populace are currently being considered through increased public-
private partnerships, research funding, international collaborations,
and generation of local revenue through provision of consultancy
and training services.
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